


TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 053466-0401 U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/533,104
INTERNATIONAL APPLICATION NO. PCT/JP2003/13954	INTERNATIONAL FILING DATE 10/30/2003	PRIORITY DATE CLAIMED 10/30/2002
TITLE OF INVENTION HM1.24-UTILIZING CANCER VACCINES		
APPLICANT(S) FOR DO/EO/US Yong KWEE et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.	
2. <input checked="" type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.	
3. <input type="checkbox"/>	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.	
4. <input type="checkbox"/>	The US has been elected (Article 31).	
5. <input type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))	
	<input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).	
	<input type="checkbox"/> has been communicated by the International Bureau.	
	<input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)	
6. <input type="checkbox"/>	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))	
	<input type="checkbox"/> is attached hereto.	
	<input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).	
7. <input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))	
	<input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau).	
	<input type="checkbox"/> have been communicated by the International Bureau.	
	<input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.	
	<input type="checkbox"/> have not been made and will not be made.	
8. <input type="checkbox"/>	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).	
9. <input type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	
10. <input type="checkbox"/>	An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).	
Items 11 to 20 below concern other document(s) or information included:		
11. <input type="checkbox"/>	An Information Disclosure Statement, Int'l Search Report and PTO/SB/08 under 37 CFR 1.97 and 1.98.	
12. <input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.	
13. <input type="checkbox"/>	A preliminary amendment.	
14. <input type="checkbox"/>	An Application Data Sheet under 37 CFR 1.76.	
15. <input type="checkbox"/>	A substitute specification.	
16. <input type="checkbox"/>	A power of attorney and/or change of address letter.	
17. <input checked="" type="checkbox"/>	A corrected computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825	
18. <input type="checkbox"/>	A second copy of the published international application under 35 U.S.C. 154(d)(4).	
19. <input type="checkbox"/>	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).	
20. <input checked="" type="checkbox"/>	Other items of information: Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825, Corrected Sequence Listing (Paper Copy) (16 pgs.).	

U.S. APPLICATION NO. (If known, see 37 CFR. 1.5) 10/533,104	INTERNATIONAL APPLICATION NO. PCT/JP2003/13954	ATTORNEY'S DOCKET NUMBER 053466-0401	
The following fees have been submitted:			
21. <input type="checkbox"/> Basic national fee \$300		\$ 0.00	
22. <input type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$100 All other situations \$200		\$ 0.00	
23. <input type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100 International Search Report prepared and provided to the Office \$400 All other situations \$500		\$ 0.00	
TOTAL OF ABOVE 21, 22 and 23 =		\$ 0.00	
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.			
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE
69 - 100 = 0	/50 = 0	x \$250.00	\$ 0.00
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))		\$ 0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	22 - 20 = 2	x \$ 50.00	\$ 0.00
Independent Claims	4 - 3 = 1	x \$ 200.00	\$ 0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$ 360.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =		\$ 0.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.		+ \$ 0.00	
SUBTOTAL =		\$ 0.00	
Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).		\$ 0.00	
TOTAL NATIONAL FEE =		\$ 0.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 40.00 per property		\$ 0.00	
TOTAL FEES ENCLOSED =		\$ 0.00	
		Amount to be refunded:	
		charged:	
<p>a. <input type="checkbox"/> A check in the amount of \$ 0.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$ 0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>			
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.			
SEND ALL CORRESPONDENCE TO:			
 SIGNATURE <u>Stephen B. Maebius</u> NAME <u>35,264</u> REGISTRATION NUMBER			
Foley & Lardner LLP Customer Number: 22428			



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/533,104	Yong Kwee	053466-0401
		INTERNATIONAL APPLICATION NO.
		PCT/JP03/13954
		I.A. FILING DATE PRIORITY DATE
		10/30/2003 10/30/2002
CONFIRMATION NO. 5920		
371 FORMALITIES LETTER		
 *OC000000016989837*		

Date Mailed: 09/12/2005

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951**
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/533,104	PCT/JP03/13954	053466-0401

FORM PCT/DO/EO/922 (371 Formalities Notice)